drugset
Drugs / GAIA-102
last change Mar 2026 re-read 9 days ago

GAIA-102

Cell therapy

Developed for
childhood malignant neoplasm · gastric cancer · malignant pancreatic neoplasm · neuroblastoma · non-small cell lung carcinoma
Investigated by
GAIA BioMedicine Inc. · Kyushu University · Japan Agency for Medical Research and Development

Trials 3

today NCT05608148 · Ph 1 NCT05438459 · Ph 1/2 NCT05207371 · Ph 1/2
20222023202420252026202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05608148 Oct 2022 → Aug 2027 expected childhood malignant neoplasm, neuroblastoma Kyushu University Recruiting No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05438459 Jun 2022 → Mar 2032 expected gastric cancer, malignant pancreatic neoplasm Kyushu University Recruiting No outcome recorded
Phase 1/2 NCT05207371 Dec 2021 → Sep 2024 non-small cell lung carcinoma GAIA BioMedicine Inc. Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as GAIA-102 “Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)” NCT05207371 ↗
2

“Intravenous injection of GAIA-102 alone” NCT05608148 ↗

NCT05438459 ↗
Modality Cell therapy “1 vial (2 x 10\^8 cells) / dose at a fixed dose” NCT05207371 ↗
Route Intravenous “Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)” NCT05207371 ↗